By Kimberly Chin
Immunomedics Inc. said it has extended its partnership with Roche Holding Ltd. on clinical trials of their combined treatments for patients with metastatic urothelial cancer and metastatic non-small cell lung cancer.
The two companies will look at the efficacy of Immunomedics' Trodelvy treatment in combination with Roche's Tecentriq.
Roche will conduct two open-label, randomized Phase 1b/2 studies that will examine patients who have failed platinum-containing chemotherapy and have begun using Tecentriq and Trodelvy together, as well as patients who use Tecentriq alone. A second study will look at patients who take the combined treatments and docetaxel alone.
Separately, Immunomedics said it will launch a Phase 2 study of Trodelvy for its first patient who has localized triple-negative breast cancer. The treatment will be administered before tumor-removal surgery, the company said. The primary aim of the study will be to show a pathological complete response rate to the treatment, Immunomedics said.
Write to Kimberly Chin at email@example.com